Cargando...
Estimation of the Percentage of US Patients With Cancer Who Benefit From Genome-Driven Oncology
IMPORTANCE: To date, the benefit of genome-driven cancer therapy has not been quantified. OBJECTIVE: We sought to estimate the annual percentage of patients in the United States with advanced or metastatic cancer who could be eligible for and benefit from US Food and Drug Administration (FDA)-approv...
Gardado en:
| Publicado en: | JAMA Oncol |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
American Medical Association
2018
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6143048/ https://ncbi.nlm.nih.gov/pubmed/29710180 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2018.1660 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|